Interest in particulate matter (PM) air pollution has been driven by epidemiologic studies reporting adverse cardiac and respiratory health effects \[[@b3-ehp0113-001741]; [@b10-ehp0113-001741]; [@b57-ehp0113-001741]\]. To further investigate the basis for these epidemiologic findings, it is important to assess individual exposures to PM and their related health effects. Panel studies that include indoor, outdoor, personal, and fixed-site PM monitoring can provide an important link between the effects observed in a population and the effects at the individual subject level.

Panel studies often report gravimetric measures of PM. However, current research is focusing on the constituents of PM ([@b5-ehp0113-001741]). Elemental carbon (EC) is one component of PM that has been associated with respiratory health effects in children. In a 10-year study of 1,759 children, [@b13-ehp0113-001741] found a strong association between reduced annual growth in forced expiratory volume in 1 sec (FEV~1~) in children and exposure to EC, nitrogen dioxide, and acid vapor. EC, measured on quartz filters by thermal desorption, is strongly associated with, but not identical to, "black carbon" (BC), as measured by diffuse transmittance through or reflectance from a Teflon filter. In a recent study, [@b22-ehp0113-001741] reported that concentrations of traffic-related pollutants (PM, BC, total nitrogen oxides, and NO~2~) were associated with respiratory symptoms in children.

EC and BC have also been associated with cardiovascular health effects. In a study of defibrillator discharge interventions among 100 adult patients, [@b41-ehp0113-001741] found that patients with ≥10 interventions experienced increased arrhythmias in association with short-term variations in BC, NO~2~, carbon monoxide, and fine particulate mass (PM~2.5~). In a study of 269 elderly Boston, Massachusetts, residents equipped with Holter monitors, an elevated BC level was associated with a --0.1 mm ST-segment depression; this BC level predicted increased risk of ST-segment depression among those with at least one episode of that level of ST-segment depression ([@b15-ehp0113-001741]). Furthermore, in elderly subjects in Boston, BC increases were associated with a decrease in flow-mediated vascular reactivity (--12.6%; [@b39-ehp0113-001741]). These studies implicate particles whose predominant source is traffic as a risk factor for adverse health effects.

Accumulated data suggest that PM exposure may lead to pulmonary inflammation ([@b16-ehp0113-001741]; [@b26-ehp0113-001741]; [@b50-ehp0113-001741]). Chronic inflammation is a hallmark of lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) ([@b12-ehp0113-001741]) and may be aggravated in susceptible groups by PM pollution. A noninvasive method of estimating airway inflammation among sensitive groups is fractional exhaled nitric oxide (FE~NO~). Over the last decade, FE~NO~ has been shown to be reproducible, inexpensive, and easy to measure serially. FE~NO~ concentrations are also highly correlated with other markers of airway inflammation, such as sputum eosinophils and bronchial hyperresponsiveness in subjects with asthma ([@b20-ehp0113-001741]). Studies have reported positive associations between FE~NO~ and ambient PM~2.5~ exposures to air pollutants in community-based studies ([@b1-ehp0113-001741]; ([@b23-ehp0113-001741]).

Spirometry has historically been used as a method of measuring health effects of exposure to PM air pollution. Numerous panel studies have examined the effects of short-term ambient PM exposure on daily lung function \[FEV~1~, forced vital capacity (FVC), and peak expiratory flow rate (PEF)\] ([@b57-ehp0113-001741]). Subjects with asthma tended to show small PEF decrements for increases in PM~10~ and PM~2.5~ concentrations, as seen in several studies ([@b14-ehp0113-001741]; [@b40-ehp0113-001741]; [@b43-ehp0113-001741]; [@b49-ehp0113-001741]).

Another measure of respiratory health, oxygen saturation of the arterial blood (SaO~2~), has been collected in panel studies. In a study of 90 elderly subjects, [@b46-ehp0113-001741] found that SaO~2~ decreased in association with PM~10~ in the Utah Valley; however, the association was not statistically significant and may have been confounded by atmospheric pressure ([@b47-ehp0113-001741]). [@b28-ehp0113-001741] found no association of SaO~2~ and PM~10~ in a panel study of 30 subjects in Los Angeles, but [@b8-ehp0113-001741] found a reduction in oxygen saturation associated with PM~2.5~ in a 12-week repeated-measures study of 28 elderly Boston residents.

Changes in cardiac measures such as blood pressure and pulse rate, which are possible risk factors for cardiovascular morbidity and mortality, have been the focus of several PM panel studies. A study in Germany showed a consistent significant increase in blood pressure in adults in association with increased concentrations of total suspended particulates (TSP) at a central site ([@b18-ehp0113-001741]). Other studies also have shown increases in blood pressure with PM ([@b28-ehp0113-001741]; [@b31-ehp0113-001741]). [@b46-ehp0113-001741] reported an association between PM~10~ and pulse rate; a 10 μg/m^3^ increase in the previous 1--5 day average PM~10~ was associated with an average increase of 0.8 beats per minute. [@b42-ehp0113-001741] found increases in pulse rate during an air pollution episode in Europe in January 1985. However, [@b31-ehp0113-001741] found decreases in heart rate associated with indoor and outdoor PM~2.5~ and PM~10~.

Therefore, based on the literature, there is some suggestion of associations between PM and changes in FE~NO~, spirometry, SaO~2~, blood pressure, and pulse rate. To determine whether changes in these health endpoints were associated with residential and personal PM and BC exposures, we conducted a panel study in Seattle, Washington, of 16 older subjects with COPD and/or asthma. This research was part of a multicity panel study designed to evaluate geographical differences in PM and cardiorespiratory health effects due to PM exposure. The study was conducted in New York City and Seattle. Seattle was chosen because it is known to have elevated wood smoke levels in winter. Our primary hypothesis was that airway inflammation in individuals with asthma and/or COPD would be associated with PM air pollution and BC, a measure shown to represent elemental carbon.

Materials and Methods
=====================

PM exposures and health effects were measured in this panel study of susceptible subjects in Seattle during the winter of 2002--2003. The study included 16 individuals with physician-diagnosed asthma, COPD, or asthma and COPD. Those individuals diagnosed with both asthma and COPD were grouped under COPD. A seventeenth subject (\#2) did not participate in the full study period and was not included in the analyses. The health outcomes measured during the study were FE~NO~, spirometry, exhaled breath condensate, pulse oximetry, heart rate, blood pressure, symptoms, and medication use. Exhaled breath condensate and symptoms are not reported here. We collected PM~2.5~ and PM~10~ Harvard Impactor (HI; Air Diagnostics and Engineering, Inc., Naples, ME) 24-hr filter samples simultaneously at a central outdoor site, as well as outside and inside the subject's home. Marple Personal Environmental Monitors for PM~10~ (MPEM~10~; MSP Corporation, Shoreview, MN) were worn to record personal exposure. We subsequently analyzed the filters for mass, light absorbance to estimate BC, and trace elemental compositions via X-ray fluorescence. Only mass and BC are reported here.

Study subjects.
---------------

The participants were recruited from a community in north Seattle, ranged from 60--86 years of age, and were nonsmokers living alone or with other non-smokers. Each subject in the panel was asked to participate for a 12-day monitoring session. Approximately 75% of the subjects were prescribed inhaled corticosteroid therapy, and two were prescribed a leukotriene receptor antagonist (montelukast). Both of these anti-inflammation medications have been shown to prevent increases in FE~NO~ in atopic subjects with asthma ([@b20-ehp0113-001741]; [@b44-ehp0113-001741]). The remaining subjects were prescribed only inhaled albuterol as needed. Subjects filled out a questionnaire to describe their medical, residential, and occupational history before enrollment in the study. A second questionnaire was administered daily during the study period to record typical physical activity, time spent outdoors, home behavior, travel, and daily medication use. All subjects read and signed a consent form approved by the University of Washington Human Subjects Office.

Offline FE~NO~.
---------------

Exhaled breath was collected according to American Thoracic Society recommendations for offline measurement ([@b54-ehp0113-001741]); however, we collected only one sample per subject visit during the late morning of each day. Previous replicate measures with the same collection devices showed good agreement. The sample was collected daily in the subjects' homes for up to 12 consecutive days. We collected exhaled breath before taking lung function measurements because deep inspirations may affect NO concentration ([@b9-ehp0113-001741]), and subjects were asked not to eat 1 hr before collection. The subjects were instructed to inhale to nearly total lung capacity and exhale through an offline collection device (Model 280i; Sievers Ionics, Boulder, CO). The subjects repeated this inhalation--exhalation cycle twice, and the third breath was collected into a nonreactive, self-sealing Mylar-like balloon. Subjects maintained a constant flow rate (0.35 mL/sec), inhaled NO-free air during the entire procedure, and exhaled with sufficient pressure (13 cm H~2~O) to close the epiglottis and prevent contamination of the airway NO sample by nasal NO. We collected samples at the same time of day (late morning) at their residences. NO was measured within 24 hr of collection using a chemiluminescent nitrogen oxide (NO~x~) monitor (model 280i; Sievers Ionics). Multiple NO concentrations from Mylar-like bags varied by \< 2 ppb over a 24-hr period, consistent with that found by [@b19-ehp0113-001741]. The monitor was calibrated daily using zero air and 45 ppm NO.

Lung function and SaO~2~.
-------------------------

Spirometry was performed according to American Thoracic Society recommendations ([@b7-ehp0113-001741]). The subjects performed the spirometry maneuvers during the technician visit. We measured FEV~1~, FVC, FEV~1~/FVC, PEF, and MEF (mid-expiratory flow). We recorded maximum forced expiratory maneuvers using diaphragm spirometers (SMI III Spirometer; Spirometrics Inc., Gray, ME). Subjects performed the maneuvers while sitting. Each subject was asked to perform three satisfactory blows, defined as FVC and FEV~1~, agreeing within 5% and a forced expiratory time exceeding 6 sec. No more than five blows were attempted. Height, weight, age, sex, and ethnicity were determined from subject's questionnaire responses. Spirometers were kept at the subject's home and calibrated just before the test session using 3-L calibration syringes (Ohio Medical Products; Airco, Inc., Madison, WI). The use of respiratory medications was recorded daily. Three times daily (morning, mid-day, and evening) the subjects sat at rest and placed the sensor of a pulse oximeter (Nellcor Model N-20P; Nellcor, Pleasanton, CA) on the left index finger. Date, SaO~2~, and pulse rate were recorded.

Cardiac measurements.
---------------------

Blood pressure was recorded, using the left arm while at rest, during the technician visits. The blood pressure cuffs (AND UA-767; A&D Medical, Milpitas, CA) were calibrated before and after the study period. Any cardiac medications used were recorded daily.

PM mass monitoring.
-------------------

We collected 24-hr PM~2.5~ and PM~10~ measurements during each 12-day session inside and outside the subjects' residences and at a central agency site (Lynnwood) using HIs. Radiance Research (Seattle, WA) nephelometers provided continuous data on fine particles, comparable to PM~1~ ([@b30-ehp0113-001741]). The indoor and outdoor PM concentrations were measured with single-stage inertial HIs and 37-mm Teflon filters for PM~10~ and PM~2.5~. One HI~2.5~--HI~10~ pair was located inside each home in the main activity room and connected to a pump (SP 280, Air Diagnostics Inc.). Another HI~2.5~--HI~10~ pair was located outside each home and connected to a pump (SP 280). The on and off flow rates were calibrated and recorded daily with a rotameter (150-nm Tube 604; Cole-Parmer Instrument Co., Vernon Hills, IL). All HI sampling periods were for 24 hr (approximately 1100 hr to 1100 hr) at a flow rate of 10 L/min. Our research group has previously evaluated the performance of continuous PM monitors (nephelometers) and HIs used in the context of a panel study ([@b29-ehp0113-001741]).

Simultaneous data also were collected with a MPEM~10~ during the study period (24 hr for ~12~ consecutive session days). The MPEM~10~ was connected to a personal pump (400S: BGI, Inc., Waltham, MA) with a mass flow controller operated at 4 L/min. Each subject carried an MPEM~10~ in the breathing zone for 24 hr, except while sleeping or showering. The monitor was attached to the shoulder strap of either a backpack or a fanny pack that contained the air pump. When the monitor was not worn, it was placed at an elevation of 3--5 ft (e.g., on a table) close to the subjects. Field technicians visited the subjects daily to calibrate the pumps with a rotameter and to record on and off flow rates and change samplers.

We weighed the filters before and after sample collection for particle mass concentration. All filter weights were measured in either duplicate or triplicate using an electronic ultra-microbalance (UMT2: Mettler Toledo, Greifensee, Switzerland). The filters were equilibrated for at least 24 hr before weighing. We performed both equilibration and weighing inside a controlled environmental chamber with constant relative humidity (34.7°C ± 2.5%) and temperature (22.4 °C ± 1.9%) ([@b2-ehp0113-001741]). Standard protocols included the use of field blanks, filter-lot blanks, laboratory blanks, and externally certified standard weights for all gravimetric analyses for quality assurance and quality control purposes. Relative humidity, outdoor temperature, NO, and NO~2~ concentrations were monitored continuously at the Beacon Hill central site by the Washington State Department of Ecology.

Black carbon measurements.
--------------------------

We estimated BC, a measure shown to represent EC from motor vehicles and woodstoves in Seattle ([@b25-ehp0113-001741]), using an integrated plate reader ([@b27-ehp0113-001741]). It is generally agreed that the major contributor to light absorption by airborne particles is BC, and levels of BC can easily be measured by this nondestructive optical technique. The method derives absorption from the change in light transmission through a Teflon filter on which particles have been collected. We analyzed the filters from the HIs for BC (wavelength of 525 nm) after the mass measurements. The integrated plate reader was re-zeroed with a blank filter between measurements. The light absorption coefficient, *b*~ap~, was computed using the amount of light transmitted through this exposed filter, the amount transmitted through the same filter before sampling, and the volume of air that passed through the filter. We used a previously derived association between *b*~ap~ and EC in Seattle to quantify the BC concentrations ([@b25-ehp0113-001741]).

Statistical analysis.
---------------------

We hypothesized that increases in PM~2.5~ and BC are associated with increases in FE~NO~. We analyzed within-subject, within-session associations between FE~NO~ and air pollution metrics using a linear mixed effects model with random intercept, controlling for age, relative humidity, and temperature. Subjects were stratified by health status in the FE~NO~, spirometry, and SaO~2~ analyses. We put use of cardiac medications into the model as an interaction term for the blood pressure and pulse rate analyses. The model included terms for within-subject, within-session (12-day monitoring period) effects; within-subject, between-session effects; the confounding variable of temperature; and relative humidity. Our primary interest was the within-subject, within-session effects of PM~2.5~ and BC on FE~NO~ levels. Our numerous exploratory analyses, the within-subject, within-session effects of PM~2.5~, PM~10~, and BC on spirometry, SaO~2~, blood pressure, and pulse rate required use of the Bonferroni test for multiple comparisons. The Bonferroni test indicated a value of *p* \< 0.0001 was significant. Therefore, for these analyses we chose *p* \< 0.0001 as our criteria for statistical significance. We used STATA software (Stata Corp., College Station, TX). The model used was as follows:
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where *X~id~* is the PM~2.5~ reading for individual *i* on day *d*; *χ̄~i~* is the mean PM~2.5~ reading for a subject; and *med~i~* is an indicator for medication use (constant for each subject ).

Results
=======

Subject characteristics.
------------------------

Characteristics of the 16 subjects are given in [Table 1](#t1-ehp0113-001741){ref-type="table"}. On average, the subjects spent 88% of their time indoors at home, 3% of their time in transit, and 9% of their time indoors away from home. Four subjects reported having received both a doctor's diagnosis of asthma and of COPD.

Airborne concentration measurements.
------------------------------------

The measured concentrations and interquartile ranges of PM~10~, PM~2.5~, and BC are presented in [Table 2](#t2-ehp0113-001741){ref-type="table"} for all the subjects, for the 7 subjects with asthma alone, and for the 9 subjects with COPD. At the fixed-site monitor, the overall 24-hr average PM~2.5~ was 14.0 μg/m^3^, the 24-hr minimum was 1.3 μg/m^3^, and the 24-hr maximum was 44 μg/m^3^. At the same site the overall 24-hr average PM~10~ was 18.0 μg/m^3^, the 24-hr minimum was 2.5 μg/m^3^, and the 24-hr maximum was 51 μg/m^3^. The overall 24-hr average BC was 7.2 μg/m^3^, the 24-hr minimum was below detection limits, and the 24-hr maximum was 2.6 μg/m^3^.

Exhaled NO.
-----------

A total of 179 midday breath samples were collected during the 12-day monitoring periods. Average FE~NO~ levels are shown in [Table 3](#t3-ehp0113-001741){ref-type="table"}. The mean FE~NO~ levels were higher for those with COPD (25.4 ppb) than for those with asthma (19.2 ppb) or COPD and asthma (16.5 ppb). In those subjects with asthma, a 10 μg/m^3^ increase in outdoor PM~2.5~ and PM~10~, relative to each subject session average, was associated with a 4.2 ppb \[95% confidence interval (CI), 1.3--7.1; *p* = 0.004) and 5.9 ppb (95% CI, 2.9--8.9; *p* = 0.000) increase in FE~NO~, respectively. There was no association between FE~NO~ and the 24-hr measures of indoor PM~2.5~ or PM~10~. A 1 μg/m^3^ increase in outdoor, indoor, and personal BC, relative to each subject session average, was associated with a 2.3 ppb increase in FE~NO~ (95% CI, 1.08--3.57; *p* = 0.000), a 4.0 ppb increase in FE~NO~ (95% CI, 2.02--5.91; *p* = 0.000), and a 1.2 ppb increase in FE~NO~ (95% CI, 0.17--2.22; *p* = 0.02), respectively ([Table 3](#t3-ehp0113-001741){ref-type="table"}). No significant association was found between PM or BC and changes in FE~NO~ in subjects with COPD. The effect levels and confidence intervals are given in [Table 3](#t3-ehp0113-001741){ref-type="table"}.

SaO~2~, blood pressure, and pulse rate.
---------------------------------------

No associations were observed between air pollution and SaO~2~, blood pressure, or pulse rate in this study.

Discussion
==========

This study showed an association between FE~NO~ in elderly subjects with asthma and indoor and outdoor BC. Increases in FE~NO~ also were associated with outdoor PM~10~ and PM~2.5~ in these same subjects. Results of this study are consistent with our earlier study of children with asthma who were not on corti-costeroid therapy ([@b23-ehp0113-001741]). That study showed an increase of approximately 4 ppb FE~NO~ associated with a 10 μg/m^3^ increases in indoor, outdoor, personal, and central-site PM~2.5~ in Seattle. Finding a similar magnitude of response in the two different groups (children and elderly with asthma) strengthens the importance of this finding. Results of the present study also are consistent with other earlier studies in Seattle showing that hospitalizations for asthma ([@b52-ehp0113-001741]) as well as increases in asthma symptoms and increased use of rescue medications ([@b59-ehp0113-001741]; [@b53-ehp0113-001741]) are associated with fine particles in Seattle.

Our data suggest that exposure to PM~10~ may play an important role in asthma exacerbation. This significant association between FE~NO~ and PM~10~ was not surprising, especially for subjects with asthma that have narrowed airways, as the thoracic coarse particles deposit preferentially in the larger bronchial airways and these airways may be the ones with the greatest inflammation potential ([@b57-ehp0113-001741]). The observed association is supported by studies that have linked PM~10~ to pulmonary inflammation in animal models ([@b26-ehp0113-001741]) and the induction of inducible nitric oxide synthase in human bronchial epithelial cells ([@b32-ehp0113-001741]).

Other studies ([@b55-ehp0113-001741]; [@b56-ehp0113-001741]; [@b58-ehp0113-001741]) have also reported positive associations between FE~NO~ and ambient exposures to air pollutants in community-based studies. [@b1-ehp0113-001741] reported that an increase in the 24-hr average PM~2.5~ concentration of 17.7 μg/m^3^ was associated with a 1.45 ppb increase in FE~NO~ in elderly subjects with asthma and COPD in a panel study in Steubenville, Ohio. [@b11-ehp0113-001741] reported a 1-day and 2-day lag association between FE~NO~ and PM~10~, black smoke, and NO. In contrast, no increase in FE~NO~ was seen in adult subjects with asthma after exposure to concentrated coarse particles ([@b16-ehp0113-001741]) or ultrafine particles ([@b45-ehp0113-001741]). Several controlled ozone exposure studies have assessed FE~NO~ in atopic subjects with asthma ([@b36-ehp0113-001741]; [@b37-ehp0113-001741]) and healthy subjects ([@b38-ehp0113-001741]), but none has found an association.

We found that FE~NO~ was associated with PM air pollution in study participants with asthma but not those with COPD. It is interesting that five of the seven subjects with asthma were using inhaled corticosteroids, which has been associated with mitigation of eNO in air pollution studies ([@b23-ehp0113-001741]) and clinical settings ([@b9-ehp0113-001741]). This finding contrasts with that of a study of elderly subjects by [@b1-ehp0113-001741] that found a PM~2.5~ response in subjects with COPD but not asthma, although there was some overlap in the study population and medications were not recorded. In our study, levels of FE~NO~, on average, were higher in COPD than asthma subjects. Exhaled NO in stable COPD has been found to be lower than in nonsmoking asthmatics ([@b21-ehp0113-001741]), but patients with unstable COPD have higher NO levels than ex-smokers with COPD ([@b35-ehp0113-001741]).

BC may more closely identify the sources of PM than standard measures of mass concentration. The contribution of BC to total PM varies geographically and temporally due to the distribution of the combustion sources that produce BC. Although BC is a major component of diesel exhaust, it is also a major component of particles produced by burning vegetation ([@b6-ehp0113-001741]; [@b17-ehp0113-001741]; [@b34-ehp0113-001741]; [@b48-ehp0113-001741]). Recent source apportionment studies in Seattle found that burning vegetation and mobile sources are major contributors to PM~2.5~ ([@b33-ehp0113-001741]) and that burning vegetation is the dominant contributor to variations in the day-to-day BC in the winter ([@b25-ehp0113-001741]). Burning vegetation, and to a lesser extent, mobile sources, may therefore be responsible for the observed increases in FE~NO~ associated with BC.

It is somewhat surprising that we did not find an association between standard spirometry measures and association with PM~2.5~, PM~10~, and BC. An earlier study completed in Seattle during the wood-burning season ([@b24-ehp0113-001741]) showed that spirometry, specifically FVC and FEV~1~, decreased in association with increases in particulate matter air pollution in children with asthma. Another study, in Vancouver, British Columbia Canada, showed a slight but not statistically significant decrease in daily FEV~1~ change in subjects with COPD was associated with increase in PM~2.5~ ([@b4-ehp0113-001741]). In three separate longitudinal diary studies, decreases in PEF were shown to be associated with increased levels of PM~2.5~ ([@b51-ehp0113-001741]).

Our exploratory hypotheses were that increases in PM~2.5~ and BC are associated with decreases in spirometry (FEV~1~, MEF) and SaO~2~ and with increases in blood pressure and pulse rate. In our study, no significant associations were seen between these health measures and PM~2.5~, PM~10~, or BC (indoor, outdoor, personal). Some studies have found that PM~10~ and PM~2.5~ both appear to affect lung function in asthmatics ([@b57-ehp0113-001741]); however, many of the studies experienced higher mean PM concentrations (in the range of 50 μg/m^3^) than were experienced by subjects in this study. The lack of significant associations between SaO~2~ and PM has also been observed in other studies ([@b28-ehp0113-001741]). In addition, no significant associations were observed between blood pressure and pulse rate and PM~2.5~, PM~10~, and BC in this study. This is in contrast to studies that have reported increases in blood pressure ([@b18-ehp0113-001741]; [@b28-ehp0113-001741]; [@b31-ehp0113-001741]) and pulse rate ([@b42-ehp0113-001741]; [@b46-ehp0113-001741]) with exposure to PM. Our study results are consistent with those of a larger panel study in Seattle ([@b31-ehp0113-001741]), but that study did see minor decreases in pulse rate in healthy subjects. Yet another study did find some changes in ectopic beats in subjects with COPD ([@b4-ehp0113-001741]). To our knowledge the present study is the first air pollution study simultaneously exploring FE~NO~, spirometry, and cardiac outcomes. It appears that FE~NO~ is more sensitive to changes in PM~2.5~, PM~10~, and BC than the other outcomes. This finding emphasizes the importance of including noninvasive, sensitive measures of health outcomes in panel studies.

The intensive monitoring of health effects and PM metrics in this study of susceptible individuals provides better estimates of actual exposures than epidemiologic data based on PM~2.5~ at a central site. There are, however, several limitations to this study. Relatively small numbers of subjects in each patient group (asthma, COPD, and those diagnosed with asthma and COPD) were monitored due to time constraints and technician availability. The same constraints also limited our ability to collect replicate NO measurements at a single time point. Subjects with COPD have difficulty performing spirometry. Also, relatively low ambient PM concentrations were experienced during the study period. That there were weaker associations between FE~NO~ and personal PM or BC may be explained by small sample air volumes, especially for the 4 L/minute personal PM~10~ samples, and the higher relative measurement error for these samples.

In conclusion, these data implicate combustion-derived PM, as measured by light absorption coefficient primarily from wood burning, as being associated with airway inflammation in adult subjects with asthma. Further, these data support the fact that FE~NO~ is a relatively simple, noninvasive measure to explore the mechanisms responsible for respiratory effects in air pollution epidemiologic field studies. Further research on susceptible populations is needed to understand the association between combustion-derived PM and airway inflammation.
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###### 

Subject characteristics of the 16 study participants.

  Health        Subject   Age   Sex   FEV~1~   Percent predicted FEV~1~   Mean FE~NO~ (ppb)   Group mean FE~NO~ (ppb)   Medication use
  ------------- --------- ----- ----- -------- -------------------------- ------------------- ------------------------- ----------------
  Asthma        1         83    F     1.35     82                         8.1 ± 3.1           19.2                      CS,B
                5         85    F     1.24     79                         9.7 ± 5.6                                     CS,I,M
                6         75    M     2.38     72                         26.8 ± 10.9                                   CS,B
                9         62    F     2.07     82                         19.4 ± 2.1                                    CS,B
                14        71    F     2.7      117                        26.4 ± 6.9                                    
                15        86    M     1.46     66                         32.9 ± 8.4                                    CS
                17        60    F     1.99     85                         11.3 ± 3.1                                    
  COPD/asthma   3         73    M     0.85     42                         10.8 ± 4.8          16.5                      I,B
                4         79    M     1.17     37                         10.5 ± 4.4                                    CS,B
                8         77    F     1.95     52                         10 ± 4.1                                      CS,B
                11        75    M     1.6      61                         33.3 ± 14.7                                   CS,B,I
                12        76    F     0.74     39                         11.2 ± 6.1                                    CS,M
  COPD          7         76    M     1.95     56                         24 ± 10             25.4                      
                10        76    F     0.78     43                         14.4 ± 8.3                                    CS,B
                13        78    M     2.41     83                         24.4 ± 8.9                                    B
                16        74    F     0.57     27                         54.3 ± 28.6                                   CS
  Mean                    75          1.6      64                         20.5                                          

Abbreviations: B, beta-agonist; CS, corticosteroid; I, ipratropium bromide; M, montelukast.

###### 

Mean (interquartile range) daily residential airborne concentration measurements (μg/m^3^) for all subjects during the study period.

  Pollution   Monitoring location     All subjects    Asthma (*n* = 7)   COPD (*n* = 9)
  ----------- ----------------------- --------------- ------------------ ----------------
  PM~2.5~     Indoor                  7.29 (4.05)     7.25 (5.72)        7.33 (3.18)
              Outdoor                 10.47 (8.87)    8.99 (7.55)        11.66 (6.71)
  PM~10~      Indoor                  11.93 (6.93)    12.54 (10.19)      11.45 (4.56)
              Outdoor                 13.47 (9.53)    11.86 (8.77)       14.76 (6.14)
              Personal (Marple PEM)   23.34 (20.72)   26.88 (20.08)      19.91 (19.94)
  BC          Indoor                  1.34 (1.12)     1.21 (1.12)        1.45 (1.11)
              Outdoor                 2.01 (1.68)     1.83 (2.22)        2.15 (1.31)
              Personal (Marple PEM)   1.64 (2.05)     1.59 (2.38)        1.69 (1.78)

Interquartile range (75th percentile -- 25th percentile). Values for PM~2.5~ and PM~10~ are given as change per 10 μg/m^3^; values for BC are given as change per 1 μg/m^3^.

###### 

Associations between FE~NO~ (ppb) and 24-hr average PM~2.5~ and PM~10~ (μg/m^3^) in subjects with asthma and COPD.

                       Asthma (*n* = 7)   COPD (*n* = 9)                                                                        
  --------- ---------- ------------------ ------------------------------------------------------ --------------- ------- ------ ----------------
  PM~2.5~   Indoor     3.69               0.10                                                   −0.74 to 8.12   −0.35   0.92   −7.45 to 6.75
            Outdoor    4.23               0.004[\*](#tfn4-ehp0113-001741){ref-type="table-fn"}   1.33 to 7.13    3.83    0.19   −1.84 to 9.49
  PM~10~    Indoor     3.81               0.11                                                   −0.86 to 8.50   2.19    0.45   −3.48 to 7.87
            Outdoor    5.87               0.000[\*](#tfn4-ehp0113-001741){ref-type="table-fn"}   2.87 to 8.88    4.45    0.12   −1.11 to 10.01
            Personal   0.66               0.29                                                   −0.56 to 1.88   0.17    0.85   −1.61 to 1.96
  BC        Indoor     3.97               0.000[\*](#tfn4-ehp0113-001741){ref-type="table-fn"}   2.02 to 5.91    1.16    0.32   −1.14 to 3.45
            Outdoor    2.32               0.000[\*](#tfn4-ehp0113-001741){ref-type="table-fn"}   1.08 to 3.57    1.81    0.21   −1.00 to 4.61
            Personal   1.20               0.02[\*](#tfn4-ehp0113-001741){ref-type="table-fn"}    0.17 to 2.22    0.62    0.33   −0.62 to 1.86

Values for PM~2.5~ and PM~10~ are given as change per 10 μg/m^3^; values for BC = are given as change per 1 μg/m^3^.

Statistically significant.

[^1]: The authors declare they have no competing financial interests.
